All In Biotech

Drug Trial Radar · NCT03867123

A Study to Evaluate the Safety of LAM561 Added to Standard of Care in Newly-diagnosed Glioblastoma Patients

A Phase 1B Study of the Safety of LAM561 Administered Orally in Combination With Temozolomide (TMZ) and Radiation Therapy or With TMZ Alone in the First Line Treatment of Subjects With Glioblastoma

Last checked: Nov 19, 2026Latest source record: Feb 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

18

Actual

Start

Dec 4, 2018

Primary completion

Jul 1, 2020

Study completion Jul 1, 2020

Sponsor

Lead sponsor
Laminar PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Mar 7, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the safety and tolerability of LAM561 added to first-line treatment for subjects with newly diagnosed glioblastoma (GBM), and to determine the highest safe dose of LAM561 administered orally when added to the concurrent phase of treatment with temozolomide (TMZ) and radiation therapy (RT) or when added to the maintenance phase of treatment with TMZ (once TMZ 200 g/m2/day is started).

Conditions

  • Glioblastoma (GBM)

Interventions

  • LAM561Drug

    Arm 1: Daily for 6 weeks. Arm 2: daily, two 28-day cycles

  • RTRadiation

    In Arm 1: Fractionated focal irradiation of 1.8-2 Gy/fraction/day, 5 days/week, 6 weeks. Total dose up to 60 Gy

  • TMZDrug

    Arm 1: 75 mg/m2/day, daily, 6 weeks Arm 2: 200 mg/m2/day, daily the first 5 days of two 28-day cycles (in case of toxicity, TMZ dose may be reduced to 150 mg/m2/day at Cycle 3 to allow for recovery)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and Tolerability of LAM561 in association with Standard of Care (Stupp Protocol)Time frame: 10 to 12 weeks
  2. Maximum Tolerated dose (MTD)Time frame: 10 to 12 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Institut Catala d'Oncologia, Hospital Germans Trias I Pujol

    Badalona, Catalonia, Spain

  • Hospital Universitari de Girona Dr. Josep Trueta, Institut Català d'Oncologia

    Girona, Catalonia, Spain

  • Hospital Duran i Reynals, Institut Català d'Oncologia

    L'Hospitalet de Llobregat, Catalonia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.